title: NicVAX (Nabi Biopharmaceuticals).
abstract: Nabi Biopharmaceuticals is developing NicVAX, a proprietary vaccine designed as a potential therapeutic to prevent and treat nicotine addiction.
authors.affiliation: The Open University, Department of Biological Sciences, Walton Hall, Milton Keynes MK7 6AA, UK. moore11@globalnet.co.uk
authors.forename: Christine E
authors.initials: CE
authors.lastname: Heading
mesh_terms: D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D009538:Nicotine / Q000276:immunology*; D013329:Structure-Activity Relationship; D014029:Tobacco Use Disorder / Q000276:immunology / Q000628:therapy*; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology*
chemical_list: D014614:Vaccines, Synthetic; D009538:Nicotine